The anti-mycobacterial activity of the cytochrome \( bcc \) inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome \( bd \)

Ping Lu\(^1\), Amer H. Asseri\(^{1,2}\), Martijn Kremer\(^1\), Janneke Maaskant\(^3\), Roy Ummels\(^3\), Holger Lill\(^1\) & Dirk Bald\(^1\)

Mycobacterial energy metabolism currently attracts strong attention as new target space for development of anti-tuberculosis drugs. The imidazopyridine Q203 targets the cytochrome \( bcc \) complex of the respiratory chain, a key component in energy metabolism. Q203 blocks growth of *Mycobacterium tuberculosis* at nanomolar concentrations, however, it fails to actually kill the bacteria, which may limit the clinical applicability of this candidate drug. In this report we show that inhibition of cytochrome \( bd \), a parallel branch of the mycobacterial respiratory chain, by aurachin D invoked bactericidal activity of Q203. In biochemical assays using inverted membrane vesicles from *Mycobacterium tuberculosis* and *Mycobacterium smegmatis* we found that inhibition of respiratory chain activity by Q203 was incomplete, but could be enhanced by inactivation of cytochrome \( bd \), either by genetic knock-out or by inhibition with aurachin D. These results indicate that simultaneously targeting the cytochrome \( bcc \) and the cytochrome \( bd \) branch of the mycobacterial respiratory chain may turn out as effective strategy for combating *M. tuberculosis*.

Tuberculosis (TB) chemotherapy has averted 49 million deaths globally between 2000 and 2015, but important treatment gaps still persist\(^1\). The global tuberculosis epidemic is larger than previously estimated. In 2015, 10.4 million people fell ill with TB, among them 480000 cases of multi-drug resistant TB, and 1.4 million TB patients died in this year\(^1\). The WHO ‘End TB’ strategy calls for a drastic reduction of both TB deaths and TB incident rates by 2030. In order to address this unmet medical need and to move forward towards the ‘End TB’ goal, the development of new TB drugs and the design of effective drug combinations is needed.

New TB drugs have been discovered and currently are evaluated in clinical trials. The regulatory approval of the ATP synthase inhibitor bedaquiline (BDQ), the first within 40 years for a TB drug, validated the oxidative phosphorylation pathway in *Mycobacterium tuberculosis* as target for treatment of tuberculosis\(^2–5\). Small molecules inhibiting various components of this key energy metabolic pathway have recently been identified\(^6–9\).

In oxidative phosphorylation, electrons flow along the enzymes of the respiratory chain and are finally used for reduction of molecular oxygen. Coupled to this electron transport, a proton motive force across the bacterial cytoplasmic membrane is established by the respiratory chain enzyme complexes. The energy of the proton motive force in turn is utilized by the ATP synthase enzyme for synthesis of ATP. In *M. tuberculosis*, the respiratory chain and ATP synthase are required for growth and for survival. Impairment of the respiratory chain functionality causes a rapid loss of cell viability\(^10,11\).

Q203, the lead compound of the imidazopyridine amide class of drugs, targets the cytochrome \( bcc \) complex\(^12\), a variant of the cytochrome \( bc \) complex (complex III) found in the respiratory chain of mycobacteria and other actinobacteria\(^13\). Q203 potently blocks growth of *M. tuberculosis* *in vitro* and in human macrophages at lower nanomolar concentrations and also displayed activity in a mouse TB infection model\(^14–16\). These features make Q203

1Department of Molecular Cell Biology, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Earth- and Life Sciences, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands. 2Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia. 3Department of Medical Microbiology and Infection Control, VU University Medical Center, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands. Correspondence and requests for materials should be addressed to D.B. (email: d.bald@vu.nl)
bcc electron flow can be re-directed away from the cytochrome complement inhibition of respiratory chain activity by Q203. Aurachin D alone displayed dose-dependent inhibition of bacterial growth when applied alone, with a minimal inhibitory concentration for inhibition of the Mycobacterium tuberculosis strain lacking cytochrome bd [15]. In these mutants, network adaptation in the respiratory chain can lead to induction of cytochrome bd [14], which constitutes an alternative branch in the respiratory chain can lead to induction of cytochrome bd [14], which constitutes an alternative branch of the respiratory chain and has been implied in the bacterial defense against a variety of stresses [16–22]. In mycobacteria, cytochrome bd is involved in the defense against hypoxia [23], cyanide [23], hydrogen peroxide [24,25], nitric oxide [15,25], and a variety of antibacterials including BDQ [24,28–30]. Cytochrome bd also facilitates metabolic adaptation of certain Mycobacterium tuberculosis laboratory strains, including the reference strain H37Rv, to imidazopyridine-type cytochrome bcc inhibitors [29]. These adapted strains displayed considerably elevated minimal inhibitory concentrations (MICs) for Q203, effectively evading growth inhibition by these drugs [29]. Upon knock-out of cytochrome bd the susceptibility for growth inhibition by Q203 was restored [29]. In in vitro time kill kinetics experiments Q203 acted bacteriostatic against Mycobacterium tuberculosis H37Rv, even when applied at concentrations of 200–300 × MIC [26,31]. However, a recent report showed that Q203 exhibited bactericidal activity against an M. tuberculosis bd-KO strain in vitro and in a mouse infection model [31]. The adaptability of M. tuberculosis strains and the lack of bactericidal activity may significantly diminish the suitability of the cytochrome bcc complex as antibiotic target and restrict the clinical applicability of Q203 as TB drug. It has been proposed that simultaneously targeting both branches of the mycobacterial respiratory chain might be required to effectively disrupt respiration in M. tuberculosis [24,29,31,32].

In this report, we explore if small-molecule inhibition of cytochrome bd can enhance the activity of a cytochrome bcc inhibitor, Q203, against M. tuberculosis.

### Results

**Small-molecule inhibition of cytochrome bd stimulates Q203.** In line with previously reported results [29], treatment of the M. tuberculosis H37Rv strain used in our laboratory with Q203 resulted in only a marginal decrease of colony forming units (Supplementary Figure 1). We also confirmed that Q203 acted bactericidal against an M. tuberculosis strain lacking cytochrome bd (Supplementary Figure 1), as described recently [31]. Next, we set out to explore if inactivation of cytochrome bd and concomitant enhancement of Q203 activity can also be achieved by a small-molecule inhibitor. For this purpose we determined the activity of aurachin D against M. tuberculosis. Aurachin D has previously been described as inhibitor of cytochrome bd in isolated cytoplasmic membranes from Escherichia coli [26], Synechocystis PCC6803 [28] and M. smegmatis [24]. Aurachin D did not effectively inhibit growth of M. tuberculosis when applied alone, with a minimal inhibitory concentration for inhibition of growth (MIC<sub>90</sub>) > 100 μM (Table 1), likely reflecting the non-essentiality of cytochrome bd in M. tuberculosis under standard culture conditions. However, addition of aurachin D considerably enhanced growth inhibition of M. tuberculosis by Q203. The MIC decreased from 10 nM for Q203 when applied alone to 1.25 nM for Q203 in combination with aurachin D (25 μM) (Table 1). The impact of aurachin D on growth inhibition by Q203 mirrored the effect achieved by genetic inactivation of cytochrome bd (Table 1).

Next, we characterized if addition of aurachin D can invoke bactericidal activity of Q203. In kill kinetics experiments, aurachin D alone did not decrease bacterial counts within 21 days. However, addition of aurachin D converted the bacteriostatic activity of Q203 (30 × MIC) into bactericidal activity (Fig. 1A). The enhancement of Q203 activity by aurachin D was dose-dependent, with >2 log<sub>10</sub> units decrease of colony forming units (CFU) triggered by 25 μg/ml aurachin D (Fig. 1B). These results demonstrate that a cytochrome bd inhibitor can considerably stimulate the impact of a cytochrome bcc–targeting companion drug.

### Inhibition of respiratory chain activity by Q203 is incomplete but can be enhanced by aurachin D.

Next, we evaluated the ability of Q203 to inhibit its target, the cytochrome bcc complex. For safety reasons these experiments were performed with the strongly attenuated Mycobacterium tuberculosis strain mc² 6020 [34]. Q203 inhibited oxygen consumption activity of inverted membrane vesicles (IMVs) from M. tuberculosis strain 6020 in a dose-dependent manner, with an IC<sub>50</sub> of ~20 nM (Fig. 2A). However, inhibition of respiratory chain activity by Q203 was incomplete, with ~60% inhibition observed at the highest Q203 concentration tested (10 μM) (Fig. 2A). These results reveal that Q203 has high affinity for its target, but indicate that a considerable part of respiratory electron flow can be re-directed away from the cytochrome bcc complex. We then evaluated if aurachin D can complement inhibition of respiratory chain activity by Q203. Aurachin D alone displayed dose-dependent inhibition of respiratory chain activity, with maximal inhibition of ~60% at 25 μM and an IC<sub>50</sub> of ~400 nM (Fig. 2B). The combination of Q203 (10 μM) with aurachin D (400 nM) displayed significantly higher inhibition than 10 μM Q203 alone (Fig. 2C). Inhibition by this Q203/aurachin D combination was also significantly higher than the maximal inhibition achievable with Q203 alone under these conditions (assessed by one-site saturation-binding model y = 70.93 × (0.009 + x, data not shown); P < 0.050). This enhanced effect found for the Q203/aurachin D combination in the biochemical assay may explain why genetic or chemical inactivation of cytochrome bd can augment inhibition of bacterial growth and trigger bacterial killing by Q203.

| Strain                  | aurachin D (μg/ml) | Q203 (nM) | Q203 (nM) + aurachin D |
|-------------------------|-------------------|-----------|-----------------------|
| M. tuberculosis H37Rv   | >100              | 10        | 1.25                  |
| M. tuberculosis H37Rv bd-KO | >100          | 1.25      | ND                    |

Table 1. In vitro susceptibility of Mycobacterium tuberculosis for Q203 and aurachin D. Minimal inhibitory concentrations (MICs) for M. tuberculosis reference strain H37Rv and a M. tuberculosis strain lacking cytochrome bd [15] were determined using the reazurin method. Q203 + aurachin D represents the MIC for Q203 in the presence of 25 μg/ml aurachin D.
Inhibition of respiratory chain activity in *M. smegmatis* by Q203. Interestingly, the respiratory chain activity of IMVs isolated from *M. smegmatis*, a fast-growing mycobacterial strain that is not sensitive to growth inhibition by Q203 (MIC > 50 μM)\(^1\), was also efficiently blocked by Q203 (Fig. 3A, black bars). The affinity of Q203 for the cytochrome *bcc* complex in *M. smegmatis* (IC\(_{50}\) ~ 20 nM) was comparable to the affinity for *M. tuberculosis* cytochrome *bcc* in the employed assay system, although *M. tuberculosis* and *M. smegmatis* vastly differ in drug susceptibility. These results demonstrate that the lack of growth inhibition found for *M. smegmatis* is not caused by insufficient affinity of Q203 for the cytochrome *bcc* complex in *M. smegmatis*. As observed for *M. tuberculosis*, inhibition of respiratory chain activity of *M. smegmatis* IMVs by Q203 was incomplete (max. inhibition 50–80%, depending on membrane batch). IMVs isolated from an *M. smegmatis* strain lacking the cytochrome *bcc* complex\(^1\) did not show significant inhibition of respiratory chain activity by Q203 (Fig. 3A, black bars), further supporting the interpretation that cytochrome *bd* can partially compensate for inactivation of the cytochrome *bcc* complex. As observed for *M. tuberculosis*, the 10 μM Q203/400 nM aurachin D combination showed significantly stronger inhibition of *M. smegmatis* wild-type respiratory chain activity than 10 μM Q203 alone (Fig. 3C).

Consistent with these results, we found that genetic inactivation of cytochrome *bd* in *M. smegmatis*\(^2\) decreased the MIC for Q203 from > 50 μM to 2.5 μM. Apparently, cytochrome *bd* mediates sensitivity for Q203 in both *M. tuberculosis* and *M. smegmatis*. However, the moderate sensitivity of the *M. smegmatis* *bd*-KO strain compared...
to *M. tuberculosis* wild–type strain (2.5 μM versus 10 nM) suggests that in *M. smegmatis* next to cytochrome *bd* additional cellular components are involved in the defense against Q203.

**Discussion**

Development of new anti-tuberculosis drugs is urgently needed in order to combat multi-drug resistant strains of *M. tuberculosis*. For effective antibacterial compounds bactericidal instead of bacteriostatic activity is highly desirable. Absence of bactericidal activity can be regarded as an argument against further consideration of a drug candidate. As an example, the development of a new imidazopyridine sub-class, the imidazopyridine ethers, was not further pursued, in part based on lack of bactericidal activity of these compounds. Q203 efficiently blocks growth of *M. tuberculosis* at nanomolar concentrations, however, this drug acts bacteriostatic on *M. tuberculosis* and lacks bactericidal activity. Upon chemical inhibition or genetically knockout of the cytochrome *bcc* branch, respiratory electron transport through the alternate cytochrome *bd* terminal oxidase alone may be sufficient to maintain mycobacterial viability. Targeting both branches of the respiratory chain may be required for effective shutdown of mycobacterial energy conversion and concomitantly for killing *M. tuberculosis*. As proof-of-concept for this strategy, we here showed that inactivation of cytochrome *bd* by a small-molecule inhibitor or by genetic modification can turn the bacteriostatic activity of Q203 into bactericidal activity.

Our results reveal high affinity of Q203 for the cytochrome *bcc* complex, but inhibition of respiratory chain activity in *M. tuberculosis* is incomplete. We regard it as likely that imid(azo)pyridines and structurally related compounds as well as structurally not related compounds such as lansoprazol that share the cytochrome *bcc* complex as target also share incomplete respiratory chain inhibition and lack of bactericidal activity against *M. tuberculosis*. One study published during the peer-review/revision process of our work revealed incomplete growth inhibition and bacteriostatic activity for the phenoxyalkyl benzimidazoles, which are hypothesized to target the cytochrome *bcc* complex in *M. tuberculosis*.

Inhibiting the catalytic activity of cytochrome *bd* can contribute to efficient killing of *M. tuberculosis*. Interestingly, the opposite approach, killing *M. tuberculosis* based on activation of cytochrome *bd*, has recently been suggested for the triple drug combination Q203/BDQ/clofazimine. The strong bactericidal activity of this combination was attributed to increased cytochrome *bd*-mediated respiratory electron flux upon inhibition of cytochrome *bcc* by Q203, thereby facilitating production of reactive oxygen species by clofazimine. Dysregulation of cytochrome *bd* function represents an efficient strategy for weakening the defense of *M. tuberculosis* and apparently can be achieved either way, by inhibition or by activation of this survival factor.

**Materials and Methods**

**Chemicals.** Aurachin D was synthesized as described earlier and was kindly provided by Dr. Jennifer Herrmann (Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarbrücken). All other chemicals were bought from Sigma unless indicated otherwise.

**Bacterial strains and growth conditions.** A *M. tuberculosis* strain lacking cytochrome *bd* was a gift from Dr. Michael Berney (Albert Einstein College of Medicine). *M. smegmatis* mc2 155 mutants strains lacking either cytochrome *bcc* or cytochrome *bd* were gifts from by Dr. Bavesh Kana (University of Witwatersrand) and Dr.
Valerie Mizrahi (University of Cape Town). Replicating bacterial cultures were grown in Middlebrook 7H9 broth (Difco) supplied with 0.05% Tween-80 and 10% Middlebrook albumin dextrose catalase enrichment (BBL) at 37 °C with shaking. If applicable, 50 μg/mL kanamycin or 50 μg/mL hygromycin was added to the medium to select for mutant strains. The attenuated M. tuberculosis strain mc² 6020² was kindly provided by Dr. William R. Jacobs, Jr. (Albert Einstein College of Medicine). Bacterial culture were grown in 7H9 medium (Difco) supplemented with 10% (vol/vol) OADC enrichment (oleic acid-albumin-dextrose-catalase, Difco), 0.05% Tween-80, 0.2% Casaminoacids, 0.24 mg/ml Pantothenate and 0.8 mg/ml L-lysine. Culture and handling of strains were done in a Biological Safety Level 3 laboratory for M. tuberculosis H37Rv and at Biological Safety Level 2 for M. tuberculosis mc² 6020 and the M. smegmatis strains.

Determination of MICs. The resazurin microtiter assay (REMA) plate method was performed in 7H9 medium containing 10% (vol/vol) OADC enrichment (oleic acid-albumin-dextrose-catalase, Difco), 0.05% Tween-80. If applicable, 50 μg/mL hygromycin was added to the medium to select for mutant strains. Q203 and aurachin D solutions were thawed and diluted in the 7H9 medium. Serial two fold dilutions of each drug in 100 μl of 7H9 medium were prepared directly in 96-well plates. Growth controls containing no antibiotic and sterility controls without inoculation were also included. The inoculum was prepared from exponential growth mycobacterial culture adjusted to OD 0.3 then diluted 1:100 and 100 μl was used as an inoculum. The plates were covered, sealed in plastic bags, and incubated at 37 °C in the normal atmosphere. After 7 days of incubation, 40 μl of fresh prepared 0.1 mg/ml resazurin was added to each well, incubated 48 hours at 37 °C, and assessed for color development. A change from blue to pink indicates reduction of resazurin and therefore bacterial growth. The MIC was defined as the lowest drug concentration that prevented this color change.

Time-kill kinetics assay. Fast-growing (log phase) mycobacterial cultures were grown to OD 0.8 to 1. Inoculum culture was prepared by diluting original culture to OD 0.4 then dilute 1:150 to achieve colony forming units around 1×10⁶. The tested concentrations of Q203 and aurachin D were added to inoculum culture and incubated at 37 °C without shaking. At indicated antibiotic exposure time, samples were collected, serially diluted (10-fold, 10¹–10⁶) and subcultured onto 7H11 agar plates supplemented with 10% (vol/vol) OADC enrichment (oleic acid-albumin-dextrose-catalase, Difco), 0.5% glycerol, 0.4% activated charcoal. Plates were sealed in plastic bags and incubated for 28 days at 37 °C to determine colony forming units (cfu) counts. The lower limit of detection was 10 cfu/mL. All experiments were performed in duplicate.

Preparation of inverted membrane vesicles. Inverted membrane vesicles (IMVs) from the bacterial strains were prepared as described previously⁶⁻⁷. Briefly, M. smegmatis and M. tuberculosis mc² 6020 were grown in a pre-culture to late-exponential phase. Cells were sedimented by centrifugation at 6000 × g for 20 minutes. The pellet was washed with phosphate buffered saline (PBS, pH 7.4) and centrifuged at 6000 × g for 20 min. Each 5 g of cells (wet weight) was re-suspended in 10 ml of ice-cold lysis buffer (10 mM HEPES, 5 mM MgCl₂ and 10% glycerol at pH 7.5) including protease inhibitors (complete, EDTA-free; protease inhibitor cocktail tablets from Roche). Lysozyme (1.2 mg/mL), deoxyribonuclease I (1500 U, Invitrogen) and MgCl₂ (12 mM) were added. Cells were incubated with shaking for one hour at 37 °C. The lysates were passed three times through a One Shot Cell Disruptor (Thermo Electron, 40 K) to 0.83 kb to break up the cells. Unbroken cells were removed by three centrifugation steps (6000 × g for 20 min at 4 °C). The membranes were pelleted by ultracentrifugation at 222,000 × g for one hour at 4 °C. The pellet was re-suspended in lysis buffer and snap-frozen until use. The protein concentration was measured using the BCA Protein Assay kit (Pierce) as described by the manufacturer.

Oxygen consumption activity assay. Oxygen respiration and the effect of inhibitors on oxygen respiration were measured by polarography using a Clark-type electrode. The electrode was fully aerated (212 ± 1% O₂) and calibrated with sodium hydrosulfite. The inverted membrane vesicles were pre-incubated for three minutes with the inhibitors in a pre-warmed (37 °C) buffer containing 50 mM MES and 2 mM MgCl₂ (pH 6.5). NADH was added as electron donor to a final concentration of 500 μM and oxygen respiration was measured for 3 minutes. Data were normalized relative to solvent (DMSO) control for full activity and to a sample with 10 mM potassium cyanide for complete inhibition. Statistical analysis (t-test) to determine P values and fitting of experimental results with one-site binding curves was done with GraphPad Prism software.

Data availability. All data generated or analyzed during this study are included in this published article.

References
1. WHO Global tuberculosis report http://apps.who.int/medicinedocs/en/d/Jh23098en/ 2016.
2. Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223–227 (2005).
3. Koul, A. et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3, 323–324 (2007).
4. Haagsma, A. C. et al. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One 6, e23575, https://doi.org/10.1371/journal.pone.0023575 (2011).
5. Jones, D. Tuberculosis success. Nat. Rev. Drug Discov. 12, 175–176 (2013).
6. Lu, P., Lill, H. & Bald, D. ATP synthase in mycobacteria: special features and implications for a function as drug target. Biochim. Biophys. Acta 1837, 1208–1218 (2014).
7. Black, P. A. et al. Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58, 2491–2503 (2014).
8. Baldwin, D., Villellas, C., Lu, P. & Koul, A. Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery. MBio 8, e00272, https://doi.org/10.1128/mbio.00272-17 (2017).
9. Cook GM, et al. Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Direction. Microbiol. Spectr. 5 https://doi.org/10.1128/microbiolspec (2017).
10. Koul, A. et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273–25280 (2008).
Acknowledgements

The authors are indebted to Bavoesh Kana (University of Witwatersrand) and Valerie Mizrahi (University of Cape Town) for a kind gift of *M. smegmatis* bcc-KO and bd-KO strains, Michael Berney (Albert Einstein College) for a kind gift of a bd-KO strain of *M. tuberculosis* and Dr. Jennifer Herrmann (Helmholz Centre for Infection Research and Pharmaceutical Biotechnology, Saarbrücken) for a kind gift of aurachin D. The authors also wish to thank Henk Hakvoort (VU Amsterdam) for technical assistance.
Author Contributions
P.L., A.A., J.M., R.U., and H.L., designed experiments and/or analyzed data; P.L., A.A., and M.K. performed experiments; D.B. supervised and coordinated experiments; P.L. and D.B. wrote the manuscript with contributions from all co-authors, D.B. supervised the overall research.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-20989-8.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018